I. MODIFIED AGREEMENTS |
|||
Biotech Co.* | Pharma Co. | Change from original agreement | Terms/Details (Date) |
| | |||
Axiom Biotechnologies Inc.* | UCB SA (Belgium) | Extended collaboration to discover drugs for the treatment of allergic rhinitis | Terms include an up-front payment, research support, milestone payments and bonuses; the one-year contract is extendable for a second year (4/2) |
ChemCodes | GlaxoSmithKline plc (UK) | Expanded technology license agreement | The agreement extends a previous agreement centered on chemistry to include biological screening processes; the ex- tension allows ChemCodes to leverage its technology platform for drug discovery (5/6) |
Genmab A/S (Denmark; CSE:GEN) | F. Hoffmann-La Roche Ltd. (Switzerland) | Expanded agreement to create and develop human antibody therapeutics for Roche using the UltiMAb platform technology licensed from Medarex Inc. | The expanded project involves a number of new disease targets; Roche made a $20M equity investment in Genmab (6/6) |
Isis Pharmaceuticals Inc. (ISIS) | Eli Lilly and Co. | Expanded agreement for Isis' antisense technology, opening the deal up to include specific gene targets for cancer and adding to its total value | Lilly licensed Affinitac in the initial agreement that was worth as much as $400M; the expansion includes work on several preclinical antisense compounds; specifics of the value added to the deal were not disclosed (6/18) |
Neurocrine Biosciences | Wyeth (formerly American Home Products Corp.) | Extended research collaboration focused on the excitatory amino acid transporter subtype, EAAT-3, with applications to treat schizophrenia, Alzheimer's disease and other nervous system disorders | Wyeth will provide extended funding for an additional year; Neurocrine is entitled to receive payment for milestones reached and worldwide royalties on commercial sales of products that result (5/1) |
Palatin Technologies Inc. (AMEX:PTN) | Mallinckrodt Inc. (division of Tyco Healthcare; Bermuda) | Amended agreement for the marketing of Palatin's infection imaging agent, LeuTech | Mallinckrodt committed up to an additional $3.2M to cover half of Palatin's estimated expenses associated with completing the FDA review process (5/15) |
Pharmacopeia Inc. (PCOP) | NV Organon (the Netherlands) | Expanded drug discovery collaboration to include initiating a medicinal chemistry optimization program to identify candidates for development by Organon | Pharmacopeia will commit its medicinal chemistry, biology and ADME knowledge to identify optimized compounds for development (5/9) |
Pharsight Corp. (PHST) | Pfizer Inc. | Expanded clinical development partnership in which Pharsight has supplied technology to Pfizer's Sandwich, UK, and Ann Arbor, Mich., sites since 1998 | The new agreement expands the relationship to Pfizer's Groton, Conn., and La Jolla, Calif., sites; terms were not disclosed (6/12) |
Prolifix Ltd.* (UK) | Novuspharma SpA (Italy) | Acquisition of rights to the anti-angiogenic research project in which the companies were collaborating since September 2000 | The alliance conducted research into a series of Prolifix's compounds with anti-angiogenic properties, specifically those inhibiting hypoxia-inducible factor Ia; NovusPharma now has rights to the research, compounds and associated intellectual property; the acquisition price was not disclosed (5/15) |
Structural Bioinformatics Inc.* | Johnson & Johnson Pharmaceutical Research & Development LLC (unit of Johnson & Johnson) | Expanded collaboration for more structural proteomics services in support of PRD's drug discovery programs using X-ray crystallography and drug-protein co-crystallization technologies for PRD proprietary compounds | Financial terms were not disclosed (4/18) |
Telik Inc. | Sanwa Kagaku Kenkyusho Co. Ltd. (Japan) | Expanded collaboration on drug candidates to treat inflammatory diseases | Sanwa will provide funding for the research and have marketing rights in Japan and certain other Asian countries to any resulting compounds; Telik has rights in North and South America, with the companies jointly owning rights in the rest of the world (4/19) |
ViroLogic Inc. (VLGC) | Pfizer Inc. | Expanded agreement to use ViroLogic's HIV-resistance testing technology in Pfizer's HIV drug discovery and development programs | The agreement covers work performed for all of Pfizer's global research and development sites worldwide; financial terms were not disclosed (6/18) |
ViroPharma | Wyeth (formerly American Home Products Corp.) | Extended agreement for two years related to the screening phase of a hepatitis C drug | The companies will continue to split costs evenly for research and development work being done at both companies (6/19) |
II. TERMINATED AGREEMENTS | |||
Amgen Inc. (AMGN) | Roche Holding AG (Switzerland) | Agreement in which Amgen regains control over European assets and business related to two white-cell boosters that are sold in the U.S. under the names Neupogen and Neulasta | Amgen regains the rights to filgrastim (Neupogen) and pegfilgrastim (Neulasta) in the European Union, Switzerland and Norway; Amgen paid $137.5M to gain control over the assets (5/8) |
Corvas International | Pfizer Inc. | Terminated agreement to develop Corvas' anti-inflammatory product, rNIF | Pfizer returned the rights to Corvas after a Phase IIb analysis showed the product had no effect on recovery in acute ischemic stroke patients; Corvas had received $4.4M in the deal that was worth a potential $31.4M (6/17) |
DUSA Pharmaceuticals Inc. (DUSA) | Schering AG (Germany) | Terminated marketing and development agreement for Levulan PDT in dermatology | Schering terminated the agreement, and DUSA will reacquire all rights within 12 months (6/7) |
Immune | Bridge Pharma Inc. | Terminated joint venture agreement that gave Immune Network a 5% royalty interest in certain Bridge Pharma revenues | Bridge's asthma and eczema projects were part of the joint venture with Immune Network (5/23) |
Indevus Pharmaceuticals Inc. (IDEV) | Pfizer Inc. | Terminated agreement for pagoclone, a late-stage drug for general anxiety and panic | Pfizer is returning all rights to Indevus because pagoclone had failed to meet primary endpoints in several studies (6/7) |
Neose Technologies | Wyeth (formerly American Home Products Corp.) | Wyeth stopped development for P-selectin glycoprotein ligand to treat myocardial infarction, but will consider other indications | Neose will miss out on research and development support and potential milestones (5/10) |
| | |||
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
This chart includes a collaboration that occurred before April 18, 2002, but it was not listed in the previous chart. | |||
AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange | |||
